Home > Back to Publisher > Report Information

Monoclonal Antibodies in Cancer Therapy 2009-2024

Visiongain
May 7, 2009
97 Pages - SKU: VSG2292317

Attention: There is an updated edition available for this report.

Abstract Table of Contents Related Reports

Monoclonal Antibodies in Cancer Therapy 2009-2024

Monoclonal antibodies in cancer therapy - significant commercial opportunities with developing technologies and innovative products - our new report explains prospects

Monoclonal antibody-based therapies for cancer are a thriving part of the biotechnology sector, as our new market report explains. The oncology market continues to expand worldwide, with high demand for more-efficacious and better-tolerated cancer therapies. The monoclonal antibodies oncology market has been growing at a significant rate and holds high potential for continued growth in both developed and emerging geographical markets. Currently, new technologies are removing some of the drawbacks that monoclonal antibody therapies have experienced. Leading pharma companies are already investing heavily in monoclonal antibody technologies. Monoclonal antibodies with great commercial potential are in the oncology pipeline, as our new report - Monoclonal Antibodies in Cancer Therapy 2009-2024 - also explains.

The period 2009 to 2019 will reveal volatility in the monoclonal antibody therapies market as current-leading products reach peak sales and new-generation drugs emerge. Will technological advances further benefit monoclonal antibody-based therapies and their overall sales? Will better immunotoxicity profiles lead to higher revenues for products? What types of monoclonal antibody therapies will enter the market from 2009 onwards, and can they dominate this market? Where will the opportunities lie, and what are the market drivers and restraints? This report will provide you with the information that you need to understand current trends and future possibilities. In particular, we discuss prospects for the following products:

Rituxan
Avastin
Herceptin
Erbitux
Vectibix
Campath.

Comprehensive analysis of this important market area

Monoclonal Antibodies in Cancer Therapy 2009-2024 examines that market sector critically, through a comprehensive review of information sources, including consultations with relevant experts. This report provides detailed sales forecasts, discussions of pipeline developments and analysis of commercial drivers and restraints, including a SWOT analysis. There are over 55 tables and figures included. The result is a comprehensive market- and industry-centred report with detailed analyses and informed opinion.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

1 Executive Summary: 1.1 Aims of this Report; 1.2 Brief Overview of the Chapters in this Report
2 Monoclonal Antibodies for Cancer Therapy: 2.1 Oncology is the Fifth-Largest Therapeutic Class Worldwide by Total Sales; 2.2 The Oncology Market is Expanding; 2.3 Monoclonal Antibodies; 2.4 Categories of Monoclonal Antibodies for Therapeutic Use; 2.5 Current Monoclonal Antibody Cancer Therapies
3 Total World Market 2009-2024: 3.1 Summary of Key Findings; 3.2 Biotech is a Rapidly-Expanding Market; 3.3 Monoclonal Antibodies are a Central Part of the Biotech Market; 3.4 Oncology - A Major Sales Driver in the Mab Sector; 3.5 Total World Market in 2008; 3.6 Predicted Sales from 2009-2024; 3.7 The Big Three; 3.8 Generic Competition; 3.9 Chimeric Antibodies in Decline; 3.10 The Shift Towards Human Antibodies
4 Key Products Analysis: 4.1 Overview: Strong Pipeline Means Competition Will Increase; 4.2 Roche/Genentech Dominated the Market in 2008; 4.3 Rituxan/MabThera (Roche/Genentech); 4.4 Avastin (Roche/Genentech); 4.5 Herceptin (Roche/Genentech); 4.6 Erbitux (Merck/Imclone); 4.7 Vectibix (Amgen); 4.8 Campath (Bayer Schering AG)
5 SWOT Analysis for the Monoclonal Antibody Oncology Therapies Market: 5.1 Principal Drivers; 5.2 Principal Restraints
6 MAbs in the Leading Pharmaceutical Markets: 6.1 USA; 6.2 Europe; 6.3 Other Countries
7 The Monoclonal Antibody Cancer Therapies Pipeline: 7.1 New Technology - Monoclonal Antibody Fragments; 7.2 Conjugated vs. Naked Antibodies; 7.3 The Future of Human MAbs; 7.4 Competition for Prime Drug Targets; 7.5 Solid Pipeline; 7.6 Products to Watch
8 Visiongain Interviews with Relevant Experts: 8.1 Dr Janice M. Reichert, Tufts University and Editor-in-Chief of the Journal mAbs; 8.2 Dr David Blakey, AstraZeneca
9 Conclusions: 9.1 The MAb Market is Strong and Expected to Grow Stronger; 9.2 Expansion into New Markets; 9.3 Personalised Treatments Emerging; 9.4 Growth Will Eventually Slow as Expansion of the Market Drives Prices Down; 9.5 Outlook for the Future
List of Tables: Table 2.1 Summary of Types of Monoclonal Antibodies for Cancer Therapy; Table 2.2 Targets and Indications for Selected FDA-Approved Antibodies; Table 3.1 Top Selling FDA Approved Antibodies, 2008; Table 3.2 Leading Monoclonal Antibodies for Oncology Therapies, Sales ($bn) and Market Shares (%), 2008; Table 3.3 Predicted Sales ($bn) for the World Market, 2009-2024; Table 3.4 Predicted Growth Rate (%) for the World Market, 2009-2024; Table 3.5 World Sales ($bn) and Market Shares (%) for the Different Types of Oncology Monoclonal Antibodies, 2008; Table 3.6 Market Shares (%) for Chimeric, Humanised and Human Monoclonal Antibodies, 2014-2024; Table 4.1 Predicted Sales ($bn) for the World Market, 2009-2016; Table 4.2 Predicted Sales ($bn) for the World Market, 2017-2024; Table 4.3 Market Shares (%) and CAGR (%) for Selected Products, 2008 and 2014; Table 5.1 SWOT Analysis, 2009-2024; Table 5.2 Side Effects of Monoclonal Antibody Therapy Table 6.1 Leading Regions of the Monoclonal Antibody Anticancer Therapies Market, Sales ($bn) and Market Shares (%), 2008 and 2014; Table 7.1 Selected Phase III and Pre-Registration Anticancer Monoclonal Antibodies, 2008 Table 9.1 Global Monoclonal Antibody Anticancer Therapies, Sales ($bn) and Growth (%), 2008-2014
List of Figures: Figure 2.1 Sales ($bn) of Naked vs. Conjugated Monoclonal Antibodies, 2008; Figure 3.1 Market Shares (%) for the Main Categories of the Monoclonal Antibody Market for 12 Months up to Q3 2008; Figure 3.2 Sales ($bn) for the Top Three Monoclonal Antibody Oncology Therapies, 2005-2008 Figure 3.3 Sales ($bn) for Monoclonal Antibody Oncology Therapies for 12 Months up to Q3 2008; Figure 3.4 Market Shares (%) for Monoclonal Antibody Oncology Therapies for 12 Months up to Q3 2008; Figure 3.5 Predicted Sales ($bn) for the World Market, 2009-2024; Figure 3.6 Predicted Growth (%) of the World Market, 2009-2014; Figure 3.7 Predicted Sales ($bn) for the Big Three: Rituxan, Avastin and Herceptin, 2009-2014; Figure 3.8 Sales ($bn) for Different Types of Monoclonal Antibodies for Oncology, 2008 Figure 3.9 Market Shares (%) for Different Types of Monoclonal Antibodies for Oncology, 2008; Figure 3.10 Pipeline Drugs (Phase II and III) by Antibody Type, 2008; Figure 3.11 Predicted Market Shares (%) for Chimeric, Humanised and Human Monoclonal Antibodies, 2014-2024; Figure 4.1 Market Shares (%) for Companies in the Monoclonal Antibody Oncology Therapies Area, 2008; Figure 4.2 Sales ($bn) for Rituxan, 2005-2008; Figure 4.3 Sales ($bn) for Rituxan, 2009-2014; Figure 4.4 Market Share (%) for Rituxan, 2009-2014; Figure 4.5 Sales ($bn) for Rituxan/MabThera, 2009-2024; Figure 4.6 Sales ($bn) for Avastin and Rituxan, 2009-2024; Figure 4.7 Sales ($bn) for Avastin, 2005-2008; Figure 4.8 Market Share (%) for Avastin, 2009-2014; Figure 4.9 Sales ($bn) for Avastin, 2009-2024; Figure 4.10 Sales ($bn) for Herceptin, 2005-2008; Figure 4.11 Sales ($bn) for Herceptin, 2009-2024; Figure 4.12 Market Share (%) for Herceptin, 2008-2014; Figure 4.13 Sales ($bn) for Erbitux, 2005-2008; Figure 4.14 Sales ($bn) for Erbitux, Herceptin and Rituxan, 2009-2024; Figure 4.15 Sales ($bn) for Erbitux, 2009-2024; Figure 4.16 Market Share (%) for Erbitux, 2009-2014; Figure 4.17 Sales ($bn) for Vectibix, 2009-2014; Figure 4.18 Market Share (%) for Vectibix, 2009-2014; Figure 4.19 Sales ($bn) for Vectibix, 2009-2024; Figure 4.20 Sales ($bn) for Campath, 2005-2008; Figure 4.21 Sales ($bn) for Campath, 2009-2024; Figure 4.22 Market Share (%) for Campath, 2009-2014; Figure 6.1 Leading Pharmaceutical Markets, Sales ($bn), 2008, 2014, 2019 and 2024; Figure 6.2 Leading Pharmaceutical Markets, Market Shares (%), 2008, 2014, 2019 and 2024 Figure 6.3 Leading Pharmaceutical Markets, CAGR (%), 2008-2014; Figure 6.4 Comparisons of the US, European, Chinese and Indian Markets, Market Shares (%), 2008-2024; Figure 7.1 Pipeline Drugs (Phase II) by Indication, 2008 Figure 7.2 Pipeline Drugs (Phase III) by Indication, 2008

Monoclonal Antibodies in Cancer Therapy 2009-2024

Share this report

Other tasks

Research Assistance

Related Markets

Oncology/Hematology Reports

Free Alert Me service